In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Avidity Biosciences Inc (NASDAQ: RNA) closed the day trading at $45.11 down -0.09% from the previous closing price of $45.15. In other words, the price has decreased by -$0.09 from its previous closing price. On the day, 0.52 million shares were traded. RNA stock price reached its highest trading level at $46.295 during the session, while it also had its lowest trading level at $45.08.
Ratios:
For a better understanding of RNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.78 and its Current Ratio is at 15.78. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on September 24, 2024, initiated with a Buy rating and assigned the stock a target price of $59.
On August 28, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $63.
On May 03, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $40.BofA Securities initiated its Buy rating on May 03, 2024, with a $40 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 21 ’24 when LEVIN ARTHUR A sold 5,000 shares for $46.63 per share. The transaction valued at 233,168 led to the insider holds 14,830 shares of the business.
ARTHUR A LEVIN bought 8,323 shares of RNA for $419,895 on Oct 21 ’24. On Oct 16 ’24, another insider, McCarthy Teresa, who serves as the Chief Human Resources Officer of the company, sold 25,000 shares for $48.52 each. As a result, the insider received 1,213,010 and left with 94,018 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 5367142912 and an Enterprise Value of 3662477056. For the stock, the TTM Price-to-Sale (P/S) ratio is 498.42 while its Price-to-Book (P/B) ratio in mrq is 4.04. Its current Enterprise Value per Revenue stands at 345.549 whereas that against EBITDA is -12.957.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $50.78, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 1.40%, while the 200-Day Moving Average is calculated to be 41.94%.
Shares Statistics:
Over the past 3-months, RNA traded about 1.33M shares per day on average, while over the past 10 days, RNA traded about 739950 shares per day. A total of 117.12M shares are outstanding, with a floating share count of 108.62M. Insiders hold about 7.26% of the company’s shares, while institutions hold 93.19% stake in the company. Shares short for RNA as of 1728950400 were 14884198 with a Short Ratio of 11.22, compared to 1726185600 on 11979442. Therefore, it implies a Short% of Shares Outstanding of 14884198 and a Short% of Float of 15.560001000000002.
